






PHARMACEUTICAL 2019

Merrimack Pharmaceuticals INC Rank 178 of 361

The relative strengths and weaknesses of Merrimack Pharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Merrimack Pharmaceuticals INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 26% points. The greatest weakness of Merrimack Pharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 28% points.

The company's Economic Capital Ratio, given in the ranking table, is 267%, being 17% points above the market average of 250%.

Input Variable	Value in 1000 USD
Assets, Current	76,102
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	14,795
Liabilities, Non-Current	56
Other Assets	10,172
Other Compr. Net Income	-9.0
Other Expenses	-7,695
Other Liabilities	14,873
Other Net Income	17,374
Other Revenues	0
Property and Equipment	2,269
Research and Development	49,974
Selling, General and Administrative Expense	15,601

Output Variable	Value in 1000 USD
Assets	88,543
Liabilities	29,724
Expenses	57,880
Revenues	0
Stockholders Equity	58,819
Net Income	-40,506
Comprehensive Net Income	-40,510
BaseVar	96,765
ECR before LimitedLiability	148%
Economic Capital Ratio	267%